For the first time, the American Academy of Neurology has recommended exercise to improve memory and cognition in mild cognitive impairment.
Five million Americans currently have Alzheimer’s disease (AD); left unchecked, that number will balloon to 16 million by 2050. Given the debilitating nature of the disease, research has turned its focus to the prevention and early treatment of cognitive and behavioral symptoms.
Cleveland Clinic has received an $8.75 million National Institute on Aging grant for a 150-patient study of how exercise might modify genetic risk for Alzheimer’s disease.
Cleveland Clinic’s Center for Geriatric Care is teaming up with the Alzheimer’s Association to provide education and resources for patients with dementia and their care partners.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Elevated CSF levels of this protein biomarker might indicate an Alzheimer’s subtype with language or behavioral changes as an early clinical sign, a retrospective study suggests.
The PRIME study of the immunotherapy agent aducanumab for Alzheimer’s disease made big news recently. An investigator in ongoing phase 3 trials of the agent sizes up PRIME and looks to what’s next.
A recent report estimated that 35.6 million people worldwide lived with dementia in 2010. By the year 2030 this is expected to double. A Cleveland Clinic functional medicine nutritionist says healthcare providers can help patients understand the connection between cognitive function and diet.
If heeded, lessons from the slew of Alzheimer drug failures can bring us closer disease-modifying success. So say these pharma industry scientists with 100 years of collective drug development experience.
Tests for biomarkers that can identify preclinical Alzheimer’s disease are raising hopes for earlier treatments but are also raising new concerns about how the information will be used by insurers and employers.
Cleveland Clinic is now enrolling patients at three U.S. sites in a phase 3 global trial of the biologic aducanumab for treatment of mild cognitive impairment or early Alzheimer disease.